Lexaria Bioscience Corp.

Clinical trials sponsored by Lexaria Bioscience Corp., explained in plain language.

Lexaria Bioscience Corp. LEXX NASDAQ

A biotech developing drug delivery technologies.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

CBD meets diabetes drugs: could this combo be a game changer for weight and sugar?

Disease control Completed

This early-phase study tested a special form of cannabidiol (CBD) called DehydraTECH, alone or combined with GLP-1 drugs (like Ozempic), in 148 overweight or obese adults with prediabetes or type 2 diabetes. The main goal was to check safety and how the body processes the drugs, …

Phase 1 • Sponsor: Lexaria Bioscience Corp. • Aim: Disease control

Last updated Jun 27, 2026 08:10 UTC

Lexaria Bioscience Corp.

CBD meets diabetes drugs: could this combo be a game changer for weight and sugar?